Jul. 2 at 9:49 PM
One of the strongest sectors outside of AI right now is Biotech.
Oncology
$TNGX Tango Therapeutics
$ELVN Enliven Therapeutics
$RVMD Revolution Medicines
$RLAY Relay Therapeutics
$CGON CG Oncology
The non-AI capital cycle is shifting into oncology biotech! Smart money is layering tactical limit entry orders atop long-term Fibonacci volume floors, lock-floating high-velocity platforms commanding unassailable clinical moats. Kingpin RVMD accelerates its right-side PEG defense, scaling historic highs past
$185 on unprecedented Phase 3 pancreatic cancer efficacy. It pairs with CGON anchoring a massive
$1.1B liquidity fortress ahead of its late-2026 BLA filing, flanked by ELVN fresh off an upsized
$400M offering and stellar leukemia trial updates. Synthetic lethality disrupter TNGX enters key Russell Growth indexes following a powerhouse
$600M capital raise, while RLAY hardens its floor. The playbook: buy the FIB support dip on CGON or ride RVMD's velocity!
